ストックスクリーナーアプリを入手
50.69
0.62%
0.31
Ptc Therapeutics Inc (PTCT) 最新ニュース
PTC Therapeutics CEO Eric Pauwels sells $147,576 in stock By Investing.com - Investing.com Australia
PTC Therapeutics' chief accounting officer sells $88,043 in stock By Investing.com - Investing.com Australia
Hussman Strategic Advisors Inc. Buys Shares of 21,000 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics CFO sells $117,006 in stock By Investing.com - Investing.com Australia
PTC Therapeutics CEO Matthew Klein sells $390,457 in stock By Investing.com - Investing.com Nigeria
PTC Therapeutics CFO sells $117,006 in stock - Investing.com India
PTC Therapeutics EVP Scott sells $88,045 in stock - Investing.com India
PTC Therapeutics' chief accounting officer sells $88,043 in stock - Investing.com
PTC Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
PTC Therapeutics EVP Scott sells $88,045 in stock By Investing.com - Investing.com UK
PTC Therapeutics (NASDAQ:PTCT) Downgraded by StockNews.com to "Hold" - MarketBeat
PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia - Marketscreener.com
How PTC Therapeutics Will Shape Its Story at Two Major Healthcare Conferences - StockTitan
Vontobel Holding Ltd. Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
FDA accepts new drug application for vatiquinone to treat Friedreich's ataxia - Contemporary Pediatrics
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $63.00 - MarketBeat
PTC Therapeutics Says FDA Grants Priority Review to Vatiquinone NDA for Treating Friedreich's Ataxia; Shares Up Pre-Bell - Marketscreener.com
FDA grants priority review for potential Friedreich's ataxia drug - Investing.com India
Ptc Therapeutics Announces FDA Acceptance And Priority Review For Vatiquinone NDA - TradingView
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential - StockTitan
RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating - Marketscreener.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Apollon Wealth Management LLC - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $45.00 - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results - Quantisnow
PTC Therapeutics' (NASDAQ:PTCT) investors will be pleased with their solid 101% return over the last year - Simply Wall St
PTC Therapeutics (NASDAQ:PTCT) Upgraded at StockNews.com - MarketBeat
(PTCT) Trading Report - Stock Traders Daily
PTC Therapeutics rises 9% after Cantor raises price target to Street high - MSN
Rett Syndrome Market Growth Projections 2024-2034: - openPR
PTC Therapeutics (NASDAQ:PTCT) Trading 6.1% Higher Following Analyst Upgrade - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $113.00 at Cantor Fitzgerald - MarketBeat
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges - MSN
Cantor Fitzgerald Issues Negative Estimate for PTCT Earnings - MarketBeat
Duchenne Muscular Dystrophy Market Report 2034: Epidemiology - openPR
PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald - Yahoo Finance
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? - Yahoo Finance
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113 By Investing.com - Investing.com Canada
Why PTC Therapeutics (PTCT) Stock Is Rallying Today - Insider Monkey
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113 - MSN
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):